共 25 条
Ghrelin inhibits LPS-induced release of IL-6 from mouse dopaminergic neurones
被引:45
作者:
Beynon, Amy L.
[1
]
Brown, M. Rowan
[2
]
Wright, Rhiannon
[1
]
Rees, Mark I.
[1
]
Sheldon, I. Martin
[3
]
Davies, Jeffrey S.
[1
,2
]
机构:
[1] Swansea Univ, Swansea SA2 8PP, W Glam, Wales
[2] Swansea Univ, Ctr Nanohlth, Swansea SA2 8PP, W Glam, Wales
[3] Swansea Univ, Inst Life Sci, Swansea SA2 8PP, W Glam, Wales
来源:
JOURNAL OF NEUROINFLAMMATION
|
2013年
/
10卷
关键词:
Ghrelin;
Interleukin-6;
Dopamine;
Neurones;
Lipopolysaccharide;
Parkinson's disease;
SUBSTANTIA-NIGRA;
PARKINSONS-DISEASE;
MICROGLIAL ACTIVATION;
CEREBROSPINAL-FLUID;
CELLS;
INTERLEUKIN-6;
INFLAMMATION;
MACROPHAGES;
EXPRESSION;
ALZHEIMERS;
D O I:
10.1186/1742-2094-10-40
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Background: Ghrelin is an orexigenic stomach hormone that acts centrally to increase mid-brain dopamine neurone activity, amplify dopamine signaling and protect against neurotoxin-induced dopamine cell death in the mouse substantia nigra pars compacta (SNpc). In addition, ghrelin inhibits the lipopolysaccharide (LPS)-induced release of pro-inflammatory cytokines from peripheral macrophages, T-cells and from LPS stimulated microglia. Here we sought to determine whether ghrelin attenuates pro-inflammatory cytokine release from dopaminergic neurones. Findings: The dopaminergic SN4741 cell-line, which derives from the mouse substantia nigra (SN) and expresses the ghrelin-receptor (growth hormone secretagogue receptor (GHS-R)) and the ghrelin-O-acyl transferase (GOAT) enzyme, was used to determine the neuro-immunomodulatory action of ghrelin. We induced innate immune activation via LPS challenge (1 mu g/ml) of SN4741 neurones that had been pre-cultured in the presence or absence of ghrelin (1, 10, 100 nM) for 4 h. After 24 h supernatants were collected for detection of IL-1 beta (IL-1 beta), TNF alpha (TNF-alpha) and IL-6 cytokines via enzyme linked immunosorbent assay (ELISA) analysis. Nuclear translocation of the transcription factor nuclear factor kappa B (NF-kappa B) was analyzed by Western blotting, and to determine viability of treatments a cell viability assay and caspase-3 immunohistochemistry were performed. We provide evidence that while IL-1 beta and TNF-alpha were not detectable under any conditions, SN4741 neurones constitutively released IL-6 under basal conditions and treatment with LPS significantly increased IL-6 secretion. Pre-treatment of neurones with ghrelin attenuated LPS-mediated IL-6 release at 24 h, an affect that was inhibited by the GHS-R antagonist [D-Lys3]-GHRP-6. However, while ghrelin pre-treatment attenuated the LPS-mediated increase in NF-kappa B, there was no alteration in its nuclear translocation. Cell viability assay and caspase-3 immunocytochemistry demonstrated that the results were independent from activation of cytotoxic and/or apoptotic mechanisms in the neuronal population, respectively. Conclusion: Our results provide evidence that the gut-hormone, ghrelin, attenuates IL-6 secretion to LPS challenge in mid-brain dopaminergic neurones. These data suggest that ghrelin may protect against dopaminergic SN nerve cell damage or death via modulation of the innate immune response.
引用
收藏
页数:6
相关论文